Maraviroc is used clinically as an anti-HIV agent and has shown few side effects, and it was reported to reduce lung metastasis and inhibit the tumor growth of breast cancer in mice [31, 34, 40], inhibit murine xenograft growth of classical Hodgkin lymphoma [37], and inhibit the CCL5-dependent migration and invasion of ESCC cell lines [38]. Here, CCL5 is linked to esophageal squamous cell carcinoma.